The Impact of Addition of Consolidation Chemotherapy to Standard Cisplatin-Based Chemoradiotherapy in Uterine Cervical Cancer: Matter of Distant Relapse
Background. Treatment of advanced uterine cervical cancer has advanced little in the last 15 years. Although two phase III trials showed survival benefit with the addition of consolidation chemotherapy (CT) after cisplatin-based chemoradiotherapy (RTCT), it is not considered standard of care. We aim...
Gespeichert in:
| Veröffentlicht in: | Journal of oncology 2019-01, Vol.2019 (2019), p.1-9 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 9 |
|---|---|
| container_issue | 2019 |
| container_start_page | 1 |
| container_title | Journal of oncology |
| container_volume | 2019 |
| creator | Santos, Elizabeth S. Lima, João P. N. S. Chen, Michael J. Baiocchi, Glauco da Costa, Alexandre A. B. A. Maya, Joyce M. L. Souza, Ronaldo P. Ribeiro, Adriana R. G. Guimarães, Andrea P. G. Sanches, Solange M. Mantoan, Henrique Queiroz, Ana C. M. Fabri, Vanessa A. Castro, Fabrício S. |
| description | Background. Treatment of advanced uterine cervical cancer has advanced little in the last 15 years. Although two phase III trials showed survival benefit with the addition of consolidation chemotherapy (CT) after cisplatin-based chemoradiotherapy (RTCT), it is not considered standard of care. We aimed to evaluate the benefit of consolidation CT compared to no additional treatment in patients treated with RTCT. Methods. This is a retrospective study including 186 patients with FIGO stage IB2, IIA2, or IIB to IVB (paraaortic lymph nodes only) uterine cervical cancer who were treated with standard RTCT alone or RTCT followed by consolidation CT. Overall survival (OS), progression free survival (PFS), and the risk of distant and local relapses were compared between the two treatment groups. Results. At 3 years OS was 91% versus 82.3% (p=0.027), PFS 84.3% versus 54.4% (p=0.047), and distant metastasis free survival (DMFS) 80.4% versus 62.5% (p=0.027) in favor of the consolidation CT group. Multivariate analysis confirmed the benefit of consolidation CT. There was no difference in locoregional free survival (LRFS). Positive lymph node was related to a higher risk of distant relapse. In the lymph node positive subgroup consolidation CT resulted in longer OS (p=0.050), PFS (p=0.014), and DMFS (p=0.022); in the lymph node negative subgroup there was no benefit from consolidation CT. Conclusions. Use of consolidation CT resulted in longer OS and PFS, mostly due to control of distant relapses. Patients at higher risk of distant relapse showed the greatest benefit. This data generates a hypothesis that could help to better select patients to consolidation CT. |
| doi_str_mv | 10.1155/2019/1217838 |
| format | Article |
| fullrecord | <record><control><sourceid>gale_pubme</sourceid><recordid>TN_cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6432701</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><galeid>A623173001</galeid><sourcerecordid>A623173001</sourcerecordid><originalsourceid>FETCH-LOGICAL-c499t-287802450a9ccd986fd2016a18208e4462394564c9b212502fbb94b2866e4ce33</originalsourceid><addsrcrecordid>eNqNkk9v1DAQxSMEoqVw44wscUGCUNtxHJsD0hL-VSpCgvZsOc6kcZW1g-0t6jfh4-J0l23hxMkjz09v5tmvKJ4S_JqQuj6mmMhjQkkjKnGvOCRcNKVgNb5_pz4oHsV4iTFnWPKHxUGFpWCUk8Pi19kI6GQ9a5OQH9Cq722y3i116130k-31zUU7wtqnEYKer1Hy6HvSrtehR62N85QZV77TEfotGHRv97R16DxBsA5QC-HKGj2hVjsD4Q36olNuLePe25glE_oGk54jPC4eDHqK8GR3HhXnHz-ctZ_L06-fTtrVaWmYlKmkohGYZotaGtNLwYc-PwjXRFAsgDFOK8lqzozsKKE1pkPXSdZRwTkwA1V1VLzd6s6bbg29AZeCntQc7FqHa-W1VX93nB3Vhb9SnFW0wSQLvNgJBP9jAzGptY0Gpkk78JuoKCUYY4YFzujzf9BLvwku21OU4YbXnBBxS13oCZR1g89zzSKqVtkOaSp8M_bVljLBxxhg2K9MsFqCoZZgqF0wMv7srs09_CcJGXi5BUab__Wn_U85yAwM-pbOBoRk1W9gA8nA</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2407656118</pqid></control><display><type>article</type><title>The Impact of Addition of Consolidation Chemotherapy to Standard Cisplatin-Based Chemoradiotherapy in Uterine Cervical Cancer: Matter of Distant Relapse</title><source>Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals</source><source>PubMed Central Open Access</source><source>Wiley Online Library Open Access</source><source>PubMed Central</source><source>Alma/SFX Local Collection</source><creator>Santos, Elizabeth S. ; Lima, João P. N. S. ; Chen, Michael J. ; Baiocchi, Glauco ; da Costa, Alexandre A. B. A. ; Maya, Joyce M. L. ; Souza, Ronaldo P. ; Ribeiro, Adriana R. G. ; Guimarães, Andrea P. G. ; Sanches, Solange M. ; Mantoan, Henrique ; Queiroz, Ana C. M. ; Fabri, Vanessa A. ; Castro, Fabrício S.</creator><contributor>Kanat, Ozkan ; Ozkan Kanat</contributor><creatorcontrib>Santos, Elizabeth S. ; Lima, João P. N. S. ; Chen, Michael J. ; Baiocchi, Glauco ; da Costa, Alexandre A. B. A. ; Maya, Joyce M. L. ; Souza, Ronaldo P. ; Ribeiro, Adriana R. G. ; Guimarães, Andrea P. G. ; Sanches, Solange M. ; Mantoan, Henrique ; Queiroz, Ana C. M. ; Fabri, Vanessa A. ; Castro, Fabrício S. ; Kanat, Ozkan ; Ozkan Kanat</creatorcontrib><description>Background. Treatment of advanced uterine cervical cancer has advanced little in the last 15 years. Although two phase III trials showed survival benefit with the addition of consolidation chemotherapy (CT) after cisplatin-based chemoradiotherapy (RTCT), it is not considered standard of care. We aimed to evaluate the benefit of consolidation CT compared to no additional treatment in patients treated with RTCT. Methods. This is a retrospective study including 186 patients with FIGO stage IB2, IIA2, or IIB to IVB (paraaortic lymph nodes only) uterine cervical cancer who were treated with standard RTCT alone or RTCT followed by consolidation CT. Overall survival (OS), progression free survival (PFS), and the risk of distant and local relapses were compared between the two treatment groups. Results. At 3 years OS was 91% versus 82.3% (p=0.027), PFS 84.3% versus 54.4% (p=0.047), and distant metastasis free survival (DMFS) 80.4% versus 62.5% (p=0.027) in favor of the consolidation CT group. Multivariate analysis confirmed the benefit of consolidation CT. There was no difference in locoregional free survival (LRFS). Positive lymph node was related to a higher risk of distant relapse. In the lymph node positive subgroup consolidation CT resulted in longer OS (p=0.050), PFS (p=0.014), and DMFS (p=0.022); in the lymph node negative subgroup there was no benefit from consolidation CT. Conclusions. Use of consolidation CT resulted in longer OS and PFS, mostly due to control of distant relapses. Patients at higher risk of distant relapse showed the greatest benefit. This data generates a hypothesis that could help to better select patients to consolidation CT.</description><identifier>ISSN: 1687-8450</identifier><identifier>EISSN: 1687-8450</identifier><identifier>DOI: 10.1155/2019/1217838</identifier><identifier>PMID: 30984261</identifier><language>eng</language><publisher>Cairo, Egypt: Hindawi Publishing Corporation</publisher><subject>Cancer ; Cancer therapies ; Care and treatment ; Cervical cancer ; Chemotherapy ; Cisplatin ; Diseases ; Histology ; Lymphatic system ; Medical records ; Medical research ; Medicine, Experimental ; Metastasis ; Patients ; Pelvis ; Radiation therapy ; Relapse ; Womens health</subject><ispartof>Journal of oncology, 2019-01, Vol.2019 (2019), p.1-9</ispartof><rights>Copyright © 2019 Vanessa A. Fabri et al.</rights><rights>COPYRIGHT 2019 John Wiley & Sons, Inc.</rights><rights>Copyright © 2019 Vanessa A. Fabri et al. This work is licensed under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Copyright © 2019 Vanessa A. Fabri et al. 2019</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c499t-287802450a9ccd986fd2016a18208e4462394564c9b212502fbb94b2866e4ce33</citedby><cites>FETCH-LOGICAL-c499t-287802450a9ccd986fd2016a18208e4462394564c9b212502fbb94b2866e4ce33</cites><orcidid>0000-0002-1631-0105 ; 0000-0002-2038-4668 ; 0000-0003-3936-8956 ; 0000-0003-3275-7609</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktopdf>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432701/pdf/$$EPDF$$P50$$Gpubmedcentral$$Hfree_for_read</linktopdf><linktohtml>$$Uhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC6432701/$$EHTML$$P50$$Gpubmedcentral$$Hfree_for_read</linktohtml><link.rule.ids>230,314,724,777,781,882,27905,27906,53772,53774</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/30984261$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><contributor>Kanat, Ozkan</contributor><contributor>Ozkan Kanat</contributor><creatorcontrib>Santos, Elizabeth S.</creatorcontrib><creatorcontrib>Lima, João P. N. S.</creatorcontrib><creatorcontrib>Chen, Michael J.</creatorcontrib><creatorcontrib>Baiocchi, Glauco</creatorcontrib><creatorcontrib>da Costa, Alexandre A. B. A.</creatorcontrib><creatorcontrib>Maya, Joyce M. L.</creatorcontrib><creatorcontrib>Souza, Ronaldo P.</creatorcontrib><creatorcontrib>Ribeiro, Adriana R. G.</creatorcontrib><creatorcontrib>Guimarães, Andrea P. G.</creatorcontrib><creatorcontrib>Sanches, Solange M.</creatorcontrib><creatorcontrib>Mantoan, Henrique</creatorcontrib><creatorcontrib>Queiroz, Ana C. M.</creatorcontrib><creatorcontrib>Fabri, Vanessa A.</creatorcontrib><creatorcontrib>Castro, Fabrício S.</creatorcontrib><title>The Impact of Addition of Consolidation Chemotherapy to Standard Cisplatin-Based Chemoradiotherapy in Uterine Cervical Cancer: Matter of Distant Relapse</title><title>Journal of oncology</title><addtitle>J Oncol</addtitle><description>Background. Treatment of advanced uterine cervical cancer has advanced little in the last 15 years. Although two phase III trials showed survival benefit with the addition of consolidation chemotherapy (CT) after cisplatin-based chemoradiotherapy (RTCT), it is not considered standard of care. We aimed to evaluate the benefit of consolidation CT compared to no additional treatment in patients treated with RTCT. Methods. This is a retrospective study including 186 patients with FIGO stage IB2, IIA2, or IIB to IVB (paraaortic lymph nodes only) uterine cervical cancer who were treated with standard RTCT alone or RTCT followed by consolidation CT. Overall survival (OS), progression free survival (PFS), and the risk of distant and local relapses were compared between the two treatment groups. Results. At 3 years OS was 91% versus 82.3% (p=0.027), PFS 84.3% versus 54.4% (p=0.047), and distant metastasis free survival (DMFS) 80.4% versus 62.5% (p=0.027) in favor of the consolidation CT group. Multivariate analysis confirmed the benefit of consolidation CT. There was no difference in locoregional free survival (LRFS). Positive lymph node was related to a higher risk of distant relapse. In the lymph node positive subgroup consolidation CT resulted in longer OS (p=0.050), PFS (p=0.014), and DMFS (p=0.022); in the lymph node negative subgroup there was no benefit from consolidation CT. Conclusions. Use of consolidation CT resulted in longer OS and PFS, mostly due to control of distant relapses. Patients at higher risk of distant relapse showed the greatest benefit. This data generates a hypothesis that could help to better select patients to consolidation CT.</description><subject>Cancer</subject><subject>Cancer therapies</subject><subject>Care and treatment</subject><subject>Cervical cancer</subject><subject>Chemotherapy</subject><subject>Cisplatin</subject><subject>Diseases</subject><subject>Histology</subject><subject>Lymphatic system</subject><subject>Medical records</subject><subject>Medical research</subject><subject>Medicine, Experimental</subject><subject>Metastasis</subject><subject>Patients</subject><subject>Pelvis</subject><subject>Radiation therapy</subject><subject>Relapse</subject><subject>Womens health</subject><issn>1687-8450</issn><issn>1687-8450</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2019</creationdate><recordtype>article</recordtype><sourceid>RHX</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>AZQEC</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNqNkk9v1DAQxSMEoqVw44wscUGCUNtxHJsD0hL-VSpCgvZsOc6kcZW1g-0t6jfh4-J0l23hxMkjz09v5tmvKJ4S_JqQuj6mmMhjQkkjKnGvOCRcNKVgNb5_pz4oHsV4iTFnWPKHxUGFpWCUk8Pi19kI6GQ9a5OQH9Cq722y3i116130k-31zUU7wtqnEYKer1Hy6HvSrtehR62N85QZV77TEfotGHRv97R16DxBsA5QC-HKGj2hVjsD4Q36olNuLePe25glE_oGk54jPC4eDHqK8GR3HhXnHz-ctZ_L06-fTtrVaWmYlKmkohGYZotaGtNLwYc-PwjXRFAsgDFOK8lqzozsKKE1pkPXSdZRwTkwA1V1VLzd6s6bbg29AZeCntQc7FqHa-W1VX93nB3Vhb9SnFW0wSQLvNgJBP9jAzGptY0Gpkk78JuoKCUYY4YFzujzf9BLvwku21OU4YbXnBBxS13oCZR1g89zzSKqVtkOaSp8M_bVljLBxxhg2K9MsFqCoZZgqF0wMv7srs09_CcJGXi5BUab__Wn_U85yAwM-pbOBoRk1W9gA8nA</recordid><startdate>20190101</startdate><enddate>20190101</enddate><creator>Santos, Elizabeth S.</creator><creator>Lima, João P. N. S.</creator><creator>Chen, Michael J.</creator><creator>Baiocchi, Glauco</creator><creator>da Costa, Alexandre A. B. A.</creator><creator>Maya, Joyce M. L.</creator><creator>Souza, Ronaldo P.</creator><creator>Ribeiro, Adriana R. G.</creator><creator>Guimarães, Andrea P. G.</creator><creator>Sanches, Solange M.</creator><creator>Mantoan, Henrique</creator><creator>Queiroz, Ana C. M.</creator><creator>Fabri, Vanessa A.</creator><creator>Castro, Fabrício S.</creator><general>Hindawi Publishing Corporation</general><general>Hindawi</general><general>John Wiley & Sons, Inc</general><general>Hindawi Limited</general><scope>ADJCN</scope><scope>AHFXO</scope><scope>RHU</scope><scope>RHW</scope><scope>RHX</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>3V.</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>AZQEC</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>NAPCQ</scope><scope>PIMPY</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope><scope>7X8</scope><scope>5PM</scope><orcidid>https://orcid.org/0000-0002-1631-0105</orcidid><orcidid>https://orcid.org/0000-0002-2038-4668</orcidid><orcidid>https://orcid.org/0000-0003-3936-8956</orcidid><orcidid>https://orcid.org/0000-0003-3275-7609</orcidid></search><sort><creationdate>20190101</creationdate><title>The Impact of Addition of Consolidation Chemotherapy to Standard Cisplatin-Based Chemoradiotherapy in Uterine Cervical Cancer: Matter of Distant Relapse</title><author>Santos, Elizabeth S. ; Lima, João P. N. S. ; Chen, Michael J. ; Baiocchi, Glauco ; da Costa, Alexandre A. B. A. ; Maya, Joyce M. L. ; Souza, Ronaldo P. ; Ribeiro, Adriana R. G. ; Guimarães, Andrea P. G. ; Sanches, Solange M. ; Mantoan, Henrique ; Queiroz, Ana C. M. ; Fabri, Vanessa A. ; Castro, Fabrício S.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c499t-287802450a9ccd986fd2016a18208e4462394564c9b212502fbb94b2866e4ce33</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2019</creationdate><topic>Cancer</topic><topic>Cancer therapies</topic><topic>Care and treatment</topic><topic>Cervical cancer</topic><topic>Chemotherapy</topic><topic>Cisplatin</topic><topic>Diseases</topic><topic>Histology</topic><topic>Lymphatic system</topic><topic>Medical records</topic><topic>Medical research</topic><topic>Medicine, Experimental</topic><topic>Metastasis</topic><topic>Patients</topic><topic>Pelvis</topic><topic>Radiation therapy</topic><topic>Relapse</topic><topic>Womens health</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Santos, Elizabeth S.</creatorcontrib><creatorcontrib>Lima, João P. N. S.</creatorcontrib><creatorcontrib>Chen, Michael J.</creatorcontrib><creatorcontrib>Baiocchi, Glauco</creatorcontrib><creatorcontrib>da Costa, Alexandre A. B. A.</creatorcontrib><creatorcontrib>Maya, Joyce M. L.</creatorcontrib><creatorcontrib>Souza, Ronaldo P.</creatorcontrib><creatorcontrib>Ribeiro, Adriana R. G.</creatorcontrib><creatorcontrib>Guimarães, Andrea P. G.</creatorcontrib><creatorcontrib>Sanches, Solange M.</creatorcontrib><creatorcontrib>Mantoan, Henrique</creatorcontrib><creatorcontrib>Queiroz, Ana C. M.</creatorcontrib><creatorcontrib>Fabri, Vanessa A.</creatorcontrib><creatorcontrib>Castro, Fabrício S.</creatorcontrib><collection>الدوريات العلمية والإحصائية - e-Marefa Academic and Statistical Periodicals</collection><collection>معرفة - المحتوى العربي الأكاديمي المتكامل - e-Marefa Academic Complete</collection><collection>Hindawi Publishing Complete</collection><collection>Hindawi Publishing Subscription Journals</collection><collection>Hindawi Publishing Open Access</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Central (Corporate)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central Essentials</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Nursing & Allied Health Premium</collection><collection>Publicly Available Content Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><collection>MEDLINE - Academic</collection><collection>PubMed Central (Full Participant titles)</collection><jtitle>Journal of oncology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Santos, Elizabeth S.</au><au>Lima, João P. N. S.</au><au>Chen, Michael J.</au><au>Baiocchi, Glauco</au><au>da Costa, Alexandre A. B. A.</au><au>Maya, Joyce M. L.</au><au>Souza, Ronaldo P.</au><au>Ribeiro, Adriana R. G.</au><au>Guimarães, Andrea P. G.</au><au>Sanches, Solange M.</au><au>Mantoan, Henrique</au><au>Queiroz, Ana C. M.</au><au>Fabri, Vanessa A.</au><au>Castro, Fabrício S.</au><au>Kanat, Ozkan</au><au>Ozkan Kanat</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>The Impact of Addition of Consolidation Chemotherapy to Standard Cisplatin-Based Chemoradiotherapy in Uterine Cervical Cancer: Matter of Distant Relapse</atitle><jtitle>Journal of oncology</jtitle><addtitle>J Oncol</addtitle><date>2019-01-01</date><risdate>2019</risdate><volume>2019</volume><issue>2019</issue><spage>1</spage><epage>9</epage><pages>1-9</pages><issn>1687-8450</issn><eissn>1687-8450</eissn><abstract>Background. Treatment of advanced uterine cervical cancer has advanced little in the last 15 years. Although two phase III trials showed survival benefit with the addition of consolidation chemotherapy (CT) after cisplatin-based chemoradiotherapy (RTCT), it is not considered standard of care. We aimed to evaluate the benefit of consolidation CT compared to no additional treatment in patients treated with RTCT. Methods. This is a retrospective study including 186 patients with FIGO stage IB2, IIA2, or IIB to IVB (paraaortic lymph nodes only) uterine cervical cancer who were treated with standard RTCT alone or RTCT followed by consolidation CT. Overall survival (OS), progression free survival (PFS), and the risk of distant and local relapses were compared between the two treatment groups. Results. At 3 years OS was 91% versus 82.3% (p=0.027), PFS 84.3% versus 54.4% (p=0.047), and distant metastasis free survival (DMFS) 80.4% versus 62.5% (p=0.027) in favor of the consolidation CT group. Multivariate analysis confirmed the benefit of consolidation CT. There was no difference in locoregional free survival (LRFS). Positive lymph node was related to a higher risk of distant relapse. In the lymph node positive subgroup consolidation CT resulted in longer OS (p=0.050), PFS (p=0.014), and DMFS (p=0.022); in the lymph node negative subgroup there was no benefit from consolidation CT. Conclusions. Use of consolidation CT resulted in longer OS and PFS, mostly due to control of distant relapses. Patients at higher risk of distant relapse showed the greatest benefit. This data generates a hypothesis that could help to better select patients to consolidation CT.</abstract><cop>Cairo, Egypt</cop><pub>Hindawi Publishing Corporation</pub><pmid>30984261</pmid><doi>10.1155/2019/1217838</doi><tpages>9</tpages><orcidid>https://orcid.org/0000-0002-1631-0105</orcidid><orcidid>https://orcid.org/0000-0002-2038-4668</orcidid><orcidid>https://orcid.org/0000-0003-3936-8956</orcidid><orcidid>https://orcid.org/0000-0003-3275-7609</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1687-8450 |
| ispartof | Journal of oncology, 2019-01, Vol.2019 (2019), p.1-9 |
| issn | 1687-8450 1687-8450 |
| language | eng |
| recordid | cdi_pubmedcentral_primary_oai_pubmedcentral_nih_gov_6432701 |
| source | Elektronische Zeitschriftenbibliothek - Frei zugängliche E-Journals; PubMed Central Open Access; Wiley Online Library Open Access; PubMed Central; Alma/SFX Local Collection |
| subjects | Cancer Cancer therapies Care and treatment Cervical cancer Chemotherapy Cisplatin Diseases Histology Lymphatic system Medical records Medical research Medicine, Experimental Metastasis Patients Pelvis Radiation therapy Relapse Womens health |
| title | The Impact of Addition of Consolidation Chemotherapy to Standard Cisplatin-Based Chemoradiotherapy in Uterine Cervical Cancer: Matter of Distant Relapse |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-18T06%3A42%3A06IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-gale_pubme&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=The%20Impact%20of%20Addition%20of%20Consolidation%20Chemotherapy%20to%20Standard%20Cisplatin-Based%20Chemoradiotherapy%20in%20Uterine%20Cervical%20Cancer:%20Matter%20of%20Distant%20Relapse&rft.jtitle=Journal%20of%20oncology&rft.au=Santos,%20Elizabeth%20S.&rft.date=2019-01-01&rft.volume=2019&rft.issue=2019&rft.spage=1&rft.epage=9&rft.pages=1-9&rft.issn=1687-8450&rft.eissn=1687-8450&rft_id=info:doi/10.1155/2019/1217838&rft_dat=%3Cgale_pubme%3EA623173001%3C/gale_pubme%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2407656118&rft_id=info:pmid/30984261&rft_galeid=A623173001&rfr_iscdi=true |